Urteste conducts business activities focused on carrying out innovative projects. The outcome of these projects is the development and subsequent commercialisation of technology for the production of medical products for in vitro use, with a particular focus on cancer diagnostics.

At the current stage of development, the Company identifies fifteen diagnostic targets: pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, gastric cancer, oesophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukaemia, lymphoma, glioma. Each of the above-mentioned diagnostic targets may in the future become the basis for creating a new independent research project, for which the involvement of an external entity as a project concept provider will not be necessary.

The Company’s main strategic goals until 2027 will be:

1) Commercialisation of medical devices (diagnostic tests) at advanced stages of development, in particular the flagship PANURI project. Medical devices developed based on the results of the Company’s research are to be ultimately available in countries generating collectively at least 80% of global GDP.

2) Development of new innovative medical devices (diagnostic tests).


3) Further development of the Company based on cooperation with international and experienced partners.

The Company is considering commercialising the R&D results to develop a commercial medical device, i.e. diagnostic test prototypes and their manufacturing technology, in one of two ways:

(i) licensing (strategic partnership) or


(ii) sale of the technology or parts of it. 

For each of the projects, the Company’s goal will be to commercialise the developed research results intended to develop a medical device in a manner that will ensure the Company’s continued growth while increasing shareholder value.